8-K
filed 2026-08-13
confidence 95%
Item 2.02
This is a clear earnings release for Q2 2026 filed under Item 2.02. The press release discloses quarterly financial results including revenues of $2.3 million (down 68.5% YoY), net loss of $8.7 million per share, and adjusted EBITDA of negative $3 million. The filing includes consolidated statements of operations and balance sheet data, making this a standard quarterly earnings announcement material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
filed 2026-06-05
confidence 75%
Item 1.01
The Company entered into a material definitive agreement for a $15 million revolving credit facility with City National Bank of Florida on June 2, 2026. While Item 1.01 typically covers M&A transactions, this disclosure involves a significant financing arrangement with substantial collateral requirements (including $2.23 million in cash collateral and a security interest in all Company assets) and restrictive covenants that materially affect the Company's operational flexibility. The replacement of the previous Fifth Third Bank facility and the debt service coverage ratio covenant make this a material capital event, though it is more accurately a financing arrangement than a traditional M&A activity.
View raw filing on EDGAR →
8-K
filed 2026-06-02
confidence 98%
Item 5.07
This Item 5.07 disclosure reports the results of Sensus Healthcare's Annual Meeting of Stockholders held on May 29, 2026, including the election of two Class II directors (Eric Sachetta and Michael J. Sardano), an advisory vote on executive compensation, and ratification of Carr, Riggs & Ingram, LLC as independent auditor. The tabulated vote counts for each matter are provided, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →